As Shadow Health Minister, I recently responded to a debate on the UK-US Arrangement on Pharmaceutical Pricing and Tariffs, and urged the Government to publish an impact assessment of the deal.
The UK-US pharmaceutical arrangement, which will see 0.3% of GDP in 2026, rising to at least 0.6% by 2036 - or an overall medicine spend of 10% to 12% of the UK NHS budget by 2036.
That may bring benefits and investment, it may avoid tariffs, and it may help some patients get treatment faster, but those benefits do not remove the three key basic questions: what will this cost, how will it be funded, and what will the NHS have to forgo as a consequence?
